As of Nov 19, 2026, 1 of 1 active firms rate MXCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MXCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.07 – $-0.07 · 2 analysts
Next period, 2 analysts expect MaxCyte Inc to earn $-0.07 a share (range $-0.07 – $-0.07), versus — a year earlier. Full-year consensus is $-0.25, growing to $-0.23 the year after.
REVENUE · NEXT QUARTER
$8.1M
Range $7.5M – $8.8M · 2 analysts
Revenue is expected to reach $8.1M (range $7.5M – $8.8M). Full-year consensus is $34.7M, rising to $43.7M next year.
Top analysts covering MaxCyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MXCT.
#1
Mark Massaro
BTIG · Rank #220
Neutral
No targeton MXCT
Overall win rate
44%
+ Follow
#2
BS
Brendan Smith
TD Cowen
Buy
No targeton MXCT
Coverage
—
+ Follow
#3
MH
Matt Hewitt
Craig-Hallum
Buy
No targeton MXCT
Coverage
—
+ Follow
#4
HH
Helfey Hannah
Stephens & Co.
Buy
$6.00+376.2% to target
Coverage
—
+ Follow
MXCT stock forecast FAQ
What is MXCT's average 12-month price target?+
The 1 active firms with a live target average $5.00 for MaxCyte Inc over the next 12 months, ranging from a $5.00 high to a $5.00 low, as of Nov 19, 2026.
Is MXCT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover MXCT?+
1 active firms have a recognized rating on MaxCyte Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MXCT?+
Among analysts who currently cover MXCT, Mark Massaro of BTIG has the strongest overall Quantellect track record (Rank #220). Their current call is Neutral.
What is MaxCyte Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.07 – $-0.07) across 2 analysts. Full-year EPS is projected at $-0.25, rising to $-0.23 the following year.
How much revenue is MaxCyte Inc expected to report next quarter?+
Consensus revenue is $8.1M (range $7.5M – $8.8M). Full-year revenue is projected at $34.7M, growing to $43.7M next year.
Have analysts been upgrading or downgrading MXCT lately?+
As of Nov 19, 2026, 1 of 1 active firms rate MXCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MXCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.